Botulinum toxin type A
Botulinum toxin type A is the most important serotype in current clinical practice. It underpins the largest global brands, the broadest regulatory footprint, and the majority of therapeutic as well as aesthetic use cases.
Clinical relevance
Section titled “Clinical relevance”Type A dominates because it combines a predictable onset, clinically useful duration, and broad evidence across multiple indications. It is the toxin type behind products such as Botox, Dysport, Xeomin, and Nabota / Jeuveau.
Mechanistic summary
Section titled “Mechanistic summary”Like other botulinum toxins, type A enters cholinergic nerve terminals and suppresses acetylcholine release. The resulting weakening of targeted muscle activity, or reduction in glandular signaling, is temporary and localized when injection is properly performed.
Major product associations
Section titled “Major product associations”- Botox from AbbVie / Allergan
- Dysport from Ipsen
- Xeomin from Merz Pharma
- Nabota / Jeuveau linked to Daewoong Pharmaceutical and Medytox in the broader Korean market context
Common indications
Section titled “Common indications”Type A products are central to treatment of:
They are also extensively used in aesthetic facial treatments.
Interpretation of potency
Section titled “Interpretation of potency”Potency units are product-specific. A unit of one type A brand should not be assumed equivalent to a unit of another type A brand without context from clinical studies, labeling, or established treatment protocols.
Comparison with type B
Section titled “Comparison with type B”Compared with botulinum toxin type B, type A has wider commercial penetration and more familiar use in aesthetics. A broader comparison is available in Differences between botulinum toxin types.